Entering text into the input field will update the search result below

Novartis and Molecular Partners finalize licensing agreement for COVID-19 candidate

Jan. 18, 2022 6:46 AM ETMolecular Partners AG (MOLN) Stock, NVS StockBy: Dulan Lokuwithana, SA News Editor

Gratitude Concept With Heart Symbol

Eoneren/E+ via Getty Images

  • Molecular Partners (NASDAQ:MOLN) ADRs have lost ~16.1% in the pre-market after announcing a licensing agreement with Novartis (NYSE:NVS) for Ensovibep, its DARPin antiviral candidate for COVID-19. Novartis (NVS) is trading ~1.6% lower.
  • Per the terms, Novartis (NVS

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
NVS
--
MOLN
--